Aster DM Healthcare Ltd Q1 FY26: GCC Se Separation, India Mein Expansion, Valuation ICU Mein
1. At a Glance
Aster DM ek time Gulf ka hospital king tha, ab India-focused “post-surgery patient” hai. GCC business ₹13,500 Cr mein bech diya, ab sirf Indian hospitals bache. Q1 FY26 revenue 8% up at ₹1,078 Cr, PAT ₹88 Cr. ARPOB ₹44,200 hai, par P/E 93x sunke lagta hai “doctor ka bill dekh ke patient ka BP badh gaya.”
2. Introduction
Socho ek company jo Dubai mall ke paas bhi hospital chalati thi aur Kerala ke kasbe mein bhi. Ab Gulf hospitals separate, aur listed Aster DM India-only hai. Matlab patient ko bypass surgery kar diya—abhi naya dil India market ka.
Aur kya growth hai? 19 hospitals, 13 clinics, 243 labs, 217 pharmacies. Patient volume FY22 ke 2.2 Mn se FY24 mein 3.3 Mn ho gaya. Lekin promoter holding gir rahi hai (40% pe aayi), aur usme bhi 41% pledged hai. Matlab promoter bhi ICU mein drip pe.
Phir bhi, Aster ko “Best Hospital Chain FY24” mila—jo India mein award ke bina hospital banana lagbhag illegal hai.
3. Business Model – WTF Do They Even Do?
Aster DM apna revenue mainly hospitals se kamata hai (94%).
Hospitals & Clinics (94%) – Multi, tertiary, quaternary care. Cardiac, Neuro, Liver, Ortho—bas khud ko Apollo ka cousin samajh lo.
O&M Model – Asset-light contracts Tier-II/III cities mein. Yahan ARPOB lower hai, lekin capex bhi kam. Bas staff aur machines apne, building kisi aur ki.
Question: Agar ek hospital aapko bole “humara model asset-light hai,” kya aap admit honge ya dusra hospital dhoondhoge?
4. Financials Overview
Metric
Q1 FY26
Q1 FY25
Q4 FY25
YoY %
QoQ %
Revenue
1,078
1,002
1,000
7.6%
7.8%
EBITDA
202
161
182
25.5%
11.0%
PAT
88
81
86
9.1%
2.3%
EPS (₹)
1.65
1.58
1.58
4.4%
4.4%
Commentary: Revenue thoda thoda grow ho raha hai, profit bhi stable hai. Matlab ICU se patient discharge ho gaya, par abhi treadmill pe mat bhejna.
5. Valuation Discussion – Fair Value Range
Method 1: P/E
EPS annualised = 1.65 × 4 = ₹6.6
Industry P/E: 60x
Fair Value = ₹400 – ₹500
Method 2: EV/EBITDA
EV = ₹33,773 Cr
EBITDA FY25 = ~₹786 Cr
EV/EBITDA ≈ 43x (industry 20–25x)
Fair Value = ₹350 – ₹480
Method 3: P/Sales
Sales TTM = ₹4,214 Cr
Industry P/S = 4–6x
Fair Value = ₹400 – ₹600
Blended Fair Value Range: ₹380 – ₹520
⚠️ Disclaimer: Educational valuation only, not a medical prescription.
6. What’s Cooking – News, Triggers, Drama
Merger with Quality Care India (QCIL) – Blackstone-backed QCIL ka acquisition approved by CCI. Aster ab South India mein aur bada player ban raha hai.
Capex Blast – ₹1,000 Cr plan, 1,700+ new beds by FY27. Kerala aur Bangalore mein naye hospitals. Matlab “beds ke liye IPO-level expansion.”
Bengaluru 500-bed hospital – ₹580 Cr investment announced July 2025. Bangalore traffic ke saath hospital wait-time bhi guaranteed hai.
